Purpose: Co-prescription of paroxetine/fluoxetine (a strong CYP2D6 inhibitor) in metoprolol (a CYP2D6 substrate) users is common, but data on the clinical consequences of this drug-drug interaction are limited and inconclusive. Therefore, we assessed the effect of paroxetine/fluoxetine initiation on the existing treatment with metoprolol on the discontinuation and dose adjustment of metoprolol among elderly.
cytochrome P450 2D6 (CYP2D6) mediated pharmacokinetic DDI. [8] [9] [10] Metoprolol is predominantly metabolized by CYP2D6, while paroxetine and fluoxetine are strong inhibitors of the enzyme. [11] [12] [13] Consequently, co-prescription of these drugs leads to the substantial increase of the blood concentration of metoprolol and potentially induces metoprolol-related adverse drug reactions. 8, 10, 14, 15 The frequent co-administration of the drugs makes the clinical relevance of the DDI important to be determined, but so far real-world data about its clinical consequences are sparse and conflicting. Some case reports indicated that the co-medication of metoprolol and paroxetine/fluoxetine produces bradycardia and atrioventricular block in elderly. 10, 16, 17 However, another observational study found that the risk of bradycardia in the older population with the interacting combination is not different from those without the combination. 7 Therefore, the objective of this study was to investigate the clinical impact of such DDI by analyzing the effect of paroxetine or fluoxetine co-prescription to the existing treatment with metoprolol on the metoprolol discontinuation rate or defined daily dose (DDD) among elderly. Earlier discontinuation and dose adjustment of metoprolol after the initiation of paroxetine/fluoxetine are used as indicators to represent the emergence of metoprolol related side effects.
2 | METHOD
| Setting
This inception cohort study was performed using the University of Groningen prescription database IADB.nl which consists of over 1.2 million prescriptions since 1994 until 2015 from 60 community pharmacies in the Netherlands and covers approximately 600 000 anonymous individuals. The IADB provides information about the patients such as date of birth, gender and the prescribed drugs such as the date and the number of drugs being delivered to the patients, the Anatomical Therapeutic Chemical codes, the total number of DDD, duration of drug consumption, and the prescribers' code. The prescription data are updated every year, and the rate of prescription has been reported to represent the Dutch population generally. 18 Prescription data from hospital and OTC drugs are not included in this database. The IADB.
nl has been used as a reliable source of data for many pharmacoepidemiological researches.
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| Study population
The study population were all elderly (≥60 years old) in the IADB who had ever been prescribed metoprolol (C07AB02) and had a first co- 
| Exposed group and non-exposed group
The exposure group was defined as metoprolol with a paroxetine/fluoxetine co-prescription. The non-exposed groups were defined as either metoprolol with citalopram or with mirtazapine co-prescriptions.
The date of the first metoprolol-paroxetine/fluoxetine/citalopram/ mirtazepine co-prescription was defined as an index date. The combination can take place in 2 condition as follows: First, metoprolol and paroxetine/fluoxetine/citalopram/mirtazapine were co-prescribed at the same start date. Second, paroxetine/fluoxetine/citalopram/ mirtazapine were prescribed during the use of metoprolol.
Citalopram was chosen as a comparator because it is the most preferable drug of choice to be combined with metoprolol besides paroxetine/fluoxetine. 5 However, because it is a weak inhibitor of CYP2D6 (Ki = 5.1 microM), we used mirtazapine (Ki = 41 microM) as a negative control because it has a very minimal CYP2D6 inhibitory activity and has no interaction with metoprolol. 9,26-28 As a comparison, paroxetine and fluoxetine, as potent inhibitors of CYP2D6, have Ki
KEY POINTS
• The combined use of metoprolol and paroxetine or fluoxetine can lead to CYP2D6-mediated drug-drug interaction and is frequently observed in older persons.
• Compared with the combination of metoprolol with citalopram, the metoprolol-paroxetine/fluoxetine combination was not significantly associated with the risk of early discontinuation and dose adjustment of metoprolol.
• Compared with metoprolol-mirtazapine, metoprololparoxetine/fluoxetine combination was significantly associated with the risk of early discontinuation but not dose adjustment of metoprolol, notably among female older persons. value = 0.15 and 0.60 microM, respectively. 26 To see the impact of potential interaction of citalopram and metoprolol, we also compare the effect of the combination with the mirtazapine-metoprolol combination (supplementary 2).
| Outcomes
We assumed that the adverse drug reactions produced by the combination of metoprolol-paroxetine/fluoxetine would make the prescribers to decide for either an early discontinuation or a dose adjustment of metoprolol. Therefore, we used these clinical outcomes as indicators of the adverse effect of the DDI. Early discontinuation was defined as stopped within 3 months and not re-prescribed in a maximum period 
| Co-variates
Potential confounders were age, sex, dose of metoprolol without paroxetine/fluoxetine/citalopram/mirtazapine, and the number of different types of prescribed medication 1 year before the index date.
Complete list of Anatomical Therapeutic Chemicals that were checked can be found in the supplementary 1.
| Statistical analysis
The Chi-square test was used to compare the difference of gender distribution between exposed and non-exposed groups. Independent 
| RESULTS
The number of patients included as metoprolol-paroxetine/fluoxetine group, metoprolol-citalopram group, and metoprolol-mirtazapine group were 528, 673, and 625, respectively ( Figure 1 ). The large majority were female in each group (more than 60%). 
| DISCUSSION
Our study is the first cohort study to provide evidence of the effect of the metoprolol-paroxetine/fluoxetine co-prescription in elderly using community pharmacy prescription data. We found that the risk of discontinuation and dose adjustment of metoprolol in the metoprololparoxetine/fluoxetine combination is not significantly different from the metoprolol-citalopram combination but had a 43% higher risk of early discontinuation of metoprolol compared with the metoprololmirtazapine group.
The result of the metoprolol-paroxetine/fluoxetine and metoprolol-citalopram comparison is in line with a case control study performed by Kurdyak PA et al. 7 They reported that compared with the combination of non-inhibiting CYP2D6 antidepressants-metoprolol, there was no significant association of metoprolol-paroxetine/fluoxetine with the risk of bradycardia in elderly. Yet, this study has some limitations.
The first limitation is that they did not consider the weak CYP2D6 inhibitory capacity of citalopram as well as fluvoxamine in their analysis. 9, 11, 26, 33, 34 Although citalopram is considered to be safely combined with metoprolol, it is still able to increase the AUC of metoprolol approximately 2 to 3 times. 9, 33, 35 This weak inhibition may be important in the older people because of the age-related physiological changes.
Although the metabolic function of CYP2D6 is reported not to decline by aging, other CYPs such as CYP1A2, CYP2C9, CYP2C19, and CYP3A4 do. [36] [37] [38] This is important in 2 aspects. Firstly, metoprolol is mainly metabolized by CYP2D6 and secondarily metabolized by The second limitation, which also may explain our results, is that citalopram itself is associated with bradycardia which is reported more common in the older (>65 years) than in the younger population. [40] [41] [42] [43] [44] This side effect may also be more apparent in the elderly using metoprolol. Hence, the result of citaloprammetoprolol co-prescription depends not only on the mild CYP2D6 inhibitory effect of citalopram but also on the side effects of citalopram. To gain insight into the potential bias induced by those limitations, we used a combination of metoprolol-mirtazapine as a negative control for metoprolol-paroxetine/fluoxetine. Metoprolol and mirtazapine is reported to have no interaction; therefore, it may provide a good contrast for the interaction effect of metoprolol-paroxetine/fluoxetine. 9, 28 As expected, the results indicated that metoprolol-paroxetine/fluoxetine co-prescriptions had a significant risk of having early discontinuation of metoprolol.
We also found that the exposed group was a little younger than controls in the baseline characteristics. If anything such a difference may work against finding differences, we adjusted for differences to have the final adjusted odd ratio (OR).
Subgroup analysis by gender indicated that women using the interacting combination have a significant 62% increased risk of experiencing early discontinuation of metoprolol compared with those using the non-interacting combination. Meanwhile, there was no significant difference in the risk of having the outcome in the male population.
One possible explanation is the difference in the body mass index (BMI) between men and women. In this study, we did not have the information about the BMI of patients and whether the prescribed doses of metoprolol were normalized to the BMI. Therefore, it is possible that the unadjusted dose of metoprolol may be the culprit. Our results are in line with the study reported by Sharma et al on the interaction between metoprolol and diphenhydramine. 45 They found that diphenhydramine increases the AUC value of metoprolol significantly higher in women than men, but the differences still remain even after the dose correction by body weight. Another possibility is the differences in the baseline activity of CYP2D6 between males and females. However, the studies about the differences are conflicting. Walle et al and Kashuba et al reported that gender has no influence on the metabolic activity of CYP2D6. 46, 47 Meanwhile, other studies reported that women have a faster CYP2D6 metabolic activity compared with men. 48 , 49 Borobia et al also reported that the differences are existing, yet are not clinically relevant. 50 More studies are needed to investigate the underlying factors causing the differences in the effect of interaction.
Some limitations are worth to be mentioned in this study. First, there was no real information whether the patients were taking metoprolol as prescribed. Second, we had no data related to heart rate, blood pressures, or bradycardia as the best indicators to assess the side effects of metoprolol. Third, we did not check the metoprolol plasma concentration which can properly indicate the impact of interaction. Fourth, there was no information about the patient specific genetic status of CYP2D6. This is important because individuals with different CYP2D6 genotypes may have a different response toward the interaction. 39 Goryachkina et al reported that among 17 patients with acute myocardial infarction treated with the combination of metoprolol-paroxetine, there were 2 patients experiencing dose adjustments due to hypotension and bradycardia. Interestingly, these 2 patients were intermediate metabolizer for CYP2D6. 6 The reduced metabolic activity of CYP2D6 might increase the exposure of metoprolol, and this condition was corroborated by the strong inhibition of CYP2D6 by paroxetine which results in unexpected higher metoprolol plasma concentration. Furthermore, patients with ultra-rapid metabolizer (UM) genotype of CYP2D6 may also theoretically have a high risk in experiencing metoprololrelated adverse reactions. The CYP2D6 UM patients have a greater metabolic rate of metoprolol than CYP2D6 normal metabolizers. Hence, it has been suggested to increase the dose of metoprolol 2.5 times the normal daily dose for these patients. 51 It has been reported that the plasma concentration of paroxetine in CYP2D6 UM patients is very low or undetectable; therefore, the interaction is unlikely to exist, but a different scenario takes place for fluoxetine. 52 It is also extensively metabolized by CYP2D6 to its metabolite, norfluoxetine, but this metabolite also has a potent CYP2D6 inhibitory capacity. 13, 26, 53 β-blocker prescription after the first heart failure diagnosis have a tendency to discontinue their treatment (median duration from the start of β-blocker prescription until the discontinuation is approximately 6 months) if they have COPD, asthma, dementia, and more than 9 physician visits with the reported increased risk approximately 8%, 9%, 13%, and 14%, respectively. 54 We do not have information about the number of medical visits in the IADB database. However, for the comorbidities, we tried to control them by comparing the distribution of the diseases in the exposed and non-exposed groups and then, adjust the differences in the multivariate analysis (supplementary data 3). Asthma or COPD was defined as patients having a prescription for drugs used to treat obstructive airway diseases (R03). Dementia was defined as patients being prescribed with anti-dementia drugs (N06D). We found that dementia was more prevalent in the exposed groups and COPD/ asthma was not statistically different. After the adjustment of the differences in the variable distributions, we observed that the adjusted OR was comparable with the main results in both comparisons of metoprolol-paroxetine/fluoxetine and metoprolol-citalopram, and metoprololparoxetine/fluoxetine and metoprolol-mirtazapine for the 2 outcomes (supplementary data 3). Therefore, we concluded that dementia and COPD/asthma have no substantial influence on the outcomes.
In the Netherlands, despite the fact that computerized DDI alerting systems have been incorporated in the electronic prescription systems and applied before the dispensing process in the pharmacy, the combination of metoprolol-paroxetine/fluoxetine is still common in older patients. tems. The sensitivity and specificity of the DDI alerting systems are the main issues in the application of such surveillance system. [58] [59] [60] Therefore, this study is important because it can add evidence regarding the effect of the DDI so that it may increase the accuracy of the DDI alerting systems. 60, 61 In this study, we also compared the citalopram-metoprolol combination and the negative control. It seems that metoprolol which was co-prescribed with citalopram was likely to be discontinued earlier than metoprolol combined with mirtazapine especially in the females group (supplementary 2). More research is required to elucidate the potential impact of the combination on metoprolol treatment.
As a conclusion, the initiation of paroxetine/fluoxetine in metoprolol users in elderly, especially among female patients, was associated with the risk of experiencing early discontinuation of metoprolol. Hence, we recommend avoiding this combination in clinical practice because a more effective and safety drug combination is available.
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